Hot Features
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta... Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0701 | -10.7846153846 | 0.65 | 0.7999 | 0.5711 | 56140 | 0.76247055 | CS |
| 4 | -0.3802 | -39.6000416623 | 0.9601 | 1.0799 | 0.5711 | 90852 | 0.81747629 | CS |
| 12 | -0.3701 | -38.9578947368 | 0.95 | 1.1996 | 0.5711 | 176246 | 0.95233845 | CS |
| 26 | -0.3701 | -38.9578947368 | 0.95 | 1.1996 | 0.5711 | 176246 | 0.95233845 | CS |
| 52 | -0.3701 | -38.9578947368 | 0.95 | 1.1996 | 0.5711 | 176246 | 0.95233845 | CS |
| 156 | -0.3701 | -38.9578947368 | 0.95 | 1.1996 | 0.5711 | 176246 | 0.95233845 | CS |
| 260 | -0.3701 | -38.9578947368 | 0.95 | 1.1996 | 0.5711 | 176246 | 0.95233845 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.